Synonyms: Arelili® | Ariely® | HTI-1088 | HTI1088 | SHR-1316 | SHR1316
adebrelimab is an approved drug (China NMPA (2023))
Compound class:
Antibody
Comment: Adebrelimab (SHR-1316; HTI-1088) is a chimeric humanized IgG4κ anti-PD-L1 monoclonal antibody.
|
References |
1. Li J, Zhang D, Liu Z, Wang Y, Li X, Wang Z, Liang G, Yuan X, Li Y, Komorowski AL et al.. (2023)
The combined effect and mechanism of antiangiogenic drugs and PD-L1 inhibitor on cell apoptosis in triple negative breast cancer. Ann Transl Med, 11 (2): 83. [PMID:36819490] |
2. Mu L, Song Y, Zhao K, Liu Y, Fan Q, Wang X, Li Q, Wang X, Huang J. (2021)
SHR-1316, an anti-PD-L1 antibody, plus chemotherapy as the first-line treatment for advanced esophageal squamous cell carcinoma: A multicentre, phase 2 study. Thorac Cancer, 12 (9): 1373-1381. [PMID:33760397] |
3. Wang J, Zhou C, Yao W, Wang Q, Min X, Chen G, Xu X, Li X, Xu F, Fang Y et al.. (2022)
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol, 23 (6): 739-747. [PMID:35576956] |